Relating clinical trials to psychiatric practice: Part I: The case of a 13-year old on aripiprazole and fluoxetine

Journal of Psychiatric Practice

Volumn 9, Issue 4, 2003, Pages 307-313

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 4A; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUOXETINE; KETOCONAZOLE; NORFLUOXETINE; QUINIDINE;

ADOLESCENT; AGE; AUDITORY HALLUCINATION; BIOTRANSFORMATION; CASE REPORT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DELUSION; DISEASE COURSE; DOSE RESPONSE; DRUG CLEARANCE; DRUG MECHANISM; DRUG MONITORING; HOSPITALIZATION; HUMAN; HYPOACUSIS; MALE; MENTAL HEALTH; PHARMACOGENETICS; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0042844716     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200307000-00006     Document Type: Review

References (14)

1. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002;16:779-88.
2. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9.
3. Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I: The case. Journal of Psychiatric Practice 2002;8:370-6.
4. Preskorn SH. Why did Terry fall off the dose-response curve? Journal of Practical Psychiatry and Behavioral Health 1996;2:39-43.
5. Aripiprazole package insert. Bristol-Myers Squibb
6. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (Part I). Journal of Psychiatric Practice 2003;9:150-8.
7. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). Journal of Psychiatric Practice 2003;9:228-36.
8. Shad MU, Preskorn SH. Antidepressants. In: Levy RH, Thummel KE, Trager WF, et al., eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000: 563-77.
9. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
10. Preskorn SH. Series of columns on the human genome project and drug development published in the Journal of Psychiatric Practice. Can be accessed at www.preskorn.com/column4.html
11. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248-59.
12. Preskorn SH. "I don't see 'em." Journal of Practical Psychiatry and Behavioral Health 1997;3:302-7.
13. Preskorn SH. A message from Titanic. Journal of Practical Psychiatry and Behavioral Health 1998;4:236-42.
14. Preskorn SH. Series of columns on polypharmacology published in the Journal of Psychiatric Practice. Can be accessed at www.preskorn.com/column1.html.